Post by
beechguy on Aug 20, 2015 1:34pm
Potential 2016 Q1 valuation for new investors
400mm in projected revenue in US alone - with EU you can double that. There is a huge shortage of BCG (frontline for Bladder Cancer) Both Merck and Sanofi have shut down plants. Doctors are now prescribing 1/3 and 1/2 BCG doses to spread around the inventory. Only 1.5% of MCNA patients experienced mild to moderate AE in 3.5 trials. BCG is well over 30% AE. With no live pathogens, MCNA can be administered by a lab tech immediately following Post TURBT (BCG cannot be administered for 2 weeks post TURBT)with impressive results (around 40% CRR). If MCNA is approved for refractory BC, that 400mm number will swell enormously with off label use. Pfizer paid almost 6 x revenue for Abbvie, but most recent pharma acquisitions have been average 4.6 x revenue. Using 400mm peak revenue and a 4 x revenue multiplier valuation is 1.6B USD. $6.67 USD/ share ($8.54 / share CDN) With huge player Consonance Capital taking almost a 20% (at market - with no warrants)stake in the company, good things are afoot. It all starts September with FDA giving us the priority review and thumbs up on our submission. fingers crossed. GLTA
Comment by
cardu on Aug 20, 2015 2:59pm
Beechguy; I appreciate your informative posts. They are like a flower surrounded by clods of manure, and we all know who they are.
Comment by
ragingbull1327 on Aug 20, 2015 3:23pm
Ahhh. You must be talking about BIG MONEY that hides and disguised as little money. :)